報價延遲最少15分鐘:2026/04/26 04:11 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
24.11 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.19/1.54
|
|
企業價值
1.31B
|
| 資產負債 |
|
每股賬面淨值
-2.17
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
109.79M
|
|
每股收益
1.49
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States. |
